ATHERSYS, INC.; INC.;OREGON HEALTH AND SCIENCE UNIVERSITY;ATHERSYS
发明人:
DEANS, ROBERT,VANT HOF, WOUTER,MAZIARZ, RICHARD,KOVACSOVICS, MAGDALENA,STREETER, PHILIP
申请号：
NZ59602206
公开号：
NZ596022A
申请日:
2006.11.09
申请国别(地区):
NZ
年份:
2013
代理人:
摘要：
596022 Disclosed is the use of cells in the manufacture of a medicament for treating a subject at risk for or suffering from an immune dysfunction such as graft versus host disease, by an effective route and in an effective amount to treat the immune dysfunction, wherein the cells are isolated, expanded, multipotent, non-embyonic, non-germ cells that have a normal karyotype, express telomerase, oct-3/4 and rex-1, have undergone at least 10-40 cell doublings in culture, are allogeneic or xenogenic, do not provoke a deleterious immune response in the subject, and are effective to treat the immune dysfunction in the subject, and are to be administered adjunctively to one or more other treatments administered to the subject to treat the same dysfunction, to treat one or more other disorders, or both.
